A short course of BG9588 (anti–CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis

Overview of attention for article published in Arthritis and rheumatism, February 2003

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 9 news outlets
patent: 145 patents

guideline: 1 clinical guideline source

Readers on

mendeley: 104 Mendeley

So far, Altmetric has seen 18 news stories from 9 outlets.

Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies

BioSpace, 09 Apr 2025

Agreement includes the use of Tonix’s TNX-1500, as part of an immunomodulatory regimen to reduce rejection of Makana’s…

Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana's Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies

Stockwatch, 09 Apr 2025

Agreement includes the use of Tonix’s TNX-1500, as part of an immunomodulatory regimen to reduce rejection of Makana’s…

Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies

ADFN, 09 Apr 2025

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), (“Tonix”) a fully-integrated biopharmaceutical company with marketed…

Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana's Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies

benzinga, 09 Apr 2025

Agreement includes the use of Tonix's TNX-1500, as part of an immunomodulatory regimen to reduce rejection of Makana's…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 14 additional news stories.